Jasper Therapeutics (NASDAQ:JSPR) shares fell 43.7% in premarket trading after the company reported problems with one of its drug product lots.
The company disclosed that results from specific dose cohorts in its study of briquilimab in adult participants with chronic spontaneous urticaria appear to be affected by issues with one drug product lot. The problematic cohorts include the 240mg Q8W and 240mg followed by 180mg Q8W dosing regimens.
Jasper Therapeutics stated it is currently investigating the drug product lot in question and expects to have results of this investigation in the coming weeks.
As a result of the same drug product lot issue, the company announced it will stop its ETESIAN study in asthma.
The firm also plans to implement cost cutting measures to extend its cash runway while addressing these manufacturing concerns.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.